by Caitlin Kingsley | Jan 2, 2020 | News
2019 was another banner year for precision oncology with the approval of a number of drugs targeting novel genomic alterations, the availability of a third pan-cancer indication, and the commercial launch of new biomarker tests for predicting drug response, such as...
